Metformin plus temozolomide-based chemotherapy as adjuvant treatment for WHO grade III and IV malignant gliomas

Journal of B.U.ON.

Volumn 16, Issue 4, 2011, Pages 787-

  Valle, Guido ^a   Carmignani, M ^b   Brunetti, L ^c   Volpe, A R ^b  

^a CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^b UNIVERSITY OF L'AQUILA   (Italy)

^c UNIVERSITY OF CHIETI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

METFORMIN; TEMOZOLOMIDE;

CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER SURVIVAL; GLIOBLASTOMA; HUMAN; NOTE; PROGNOSIS; TREATMENT RESPONSE; WORLD HEALTH ORGANIZATION;

BRAIN NEOPLASMS; DACARBAZINE; FEMALE; GLIOMA; HUMANS; MALE; METFORMIN;

EID: 84855461973     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (6)

1. Soritau O, Tomuleasa C, Aldea A et al. Metformin plus temozolomide-based chemotherapy as adjuvant treatment for WHO grade HI and IV malignant gliomas. J BUON 2011; 16: 282-289.
2. Dowling RJO, Goodwin PJ, Stambolic V. Understanding the benefit of metformin use in cancer treatment BMC Medicine 2011; 9: 33.
3. Green AS, Chapuis N, Lacombe C et al. LKB1/AMPK/mTOR signalling pathway in hematological malignancies: From metabolism to cancer cell biology. Cell Cycle 2011; 10: 2115-2120.
4. Faivre S, Kroemer G, Raymond E. Current development of mTOR inhibitors as anticancer agents. Nature Rev Drug Disc 2006; 5: 671-688. (Pubitemid 44151605)
5. Bo S, Ciccone G, Rosato G et al. Cancer mortality reduction and metformin. A retrospective cohort study in type 2 diabetic patients. Diabetes Obes Metab 2011 (in print).
6. 3K elicits a prodifferentiation effect on glioblastoma stem-like cells. NeuroOncology 2010; 12: 1205-1219.